Tuesday, September 22, 2020
Several drug manufacturers recently announced new policies limiting covered entities from accessing 340B pricing for drugs dispensed through contract pharmacies. These policies threaten an established and relied-upon source of funding for many health systems as they deliver essential services to their communities. The impact is particularly acute for health systems using contract pharmacies to provide specialty medications to their patients. Many health systems are looking for answers as they try to understand how to mitigate this escalating issue.
In this virtual panel discussion, 340B and health system pharmacy services experts:
- Provide an overview of recent events, including drug manufacturer policies and responses from industry stakeholders including covered entities, HRSA, and professional associations
- Share how these policies impact health systems and their communities
- Outline how building or expanding in-house pharmacy services can mitigate the impact of these policies
- Explain how health systems can overcome barriers, accelerate growth, and increase impact of specialty pharmacy services
Panelists:
- Ted Slafsky, MPP, Publisher and CEO of 340B Report, Founder and Principal of Wexford Solutions
- Andy Maurer, MBA, Chief Executive Officer of Trellis Rx
- Jerry Buller, DPh, MMHC, Chief Pharmacy Officer of Trellis Rx
Learning Objectives:
At the end of this session, pharmacists and pharmacy liaison will be able to:
- Describe drug manufacturer policies limiting covered entities from accessing 340B pricing for drugs dispensed through contract pharmacies
- Discuss the impact of these policies for covered entities
- List barriers health systems may encounter when building or expanding in-house pharmacy services, particularly for specialty therapies
- Identify strategies health systems can leverage to accelerate in-house pharmacy services and enhance the clinical impact of these services for patients
